MarketInOut Stock Screener Log In | Sign Up

Summit Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
Summit Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization12,788 mln
Float152 mln
Earnings Date11/11/2026

Piotroski F-Score

2 / 9
Weak

1-Year Forecast

30.23
Transformational upside

Relative Strength

91 / 100
Top performer

Debt / Equity

0.03
Debt-free

ROE

-187
Deeply negative

ROA

-156
Deeply negative

Business Description

Summit Therapeutics is a biopharmaceutical company founded in 2003 and based in Miami, Florida, focused on developing medicines that work better for patients, doctors, and families. Its main drug candidate, ivonescimab, is a next-generation cancer treatment being tested in late-stage clinical trials for lung and colorectal cancers. The company sells its products across North America, Europe, Japan, Latin America, the Middle East, and Africa.

Key Fundamentals

EPS-1.11
ROE-187
ROIC-2,206
ROA-156
EBITDA, mln-856
EV / EBITDA-13.25
EV / EBIT-13.25

Quote Details

Last 16.03
Change -0.17 (-1.05%)
Open 16.03
Volume 3,488,285
Turnover 55,917,212
Average Volume 5,120,012

Financial Ratios

Leverage Ratio1.19
Current Ratio6.96
Price / Book19.41
Price / Tangible Book19.41
Debt / Equity0.03

Financial Strength

Piotroski F-Score 2 / 9
1-Year Target Price30.23
Short Ratio5.67
Short % of Float26.14

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 3.62% 85 / 100   
1 Month -3.95% 42 / 100   
2 Months 22.27% 93 / 100   
6 Months -0.5% 54 / 100   
1 Year -14.09% 34 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog